Thiogenesis Therapeutics Corp (TTI.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in thousands)
| 12-2024 | 12-2023 | 12-2022 | 02-2022 | 12-2021 | |
| Cash Flows From Operating Activities | |||||
| Accounts receivable | -3 | -29 | 112 | -25 | -167 |
| Accounts payable and accrued liabilities | N/A | 1,406 | N/A | N/A | N/A |
| Other Working Capital | -1,124 | 1,334 | -569 | 157 | 507 |
| Other Operating Activity | -2,794 | -5,958 | -1,633 | -199 | -1,108 |
| Operating Cash Flow | $-3,921 | $-3,248 | $-2,090 | $-67 | $-768 |
| Cash Flows From Investing Activities | |||||
| Net Acquisitions | N/A | 0 | 107 | N/A | 0 |
| Investing Cash Flow | $N/A | $0 | $107 | $N/A | $0 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | N/A | 0 | -175 | N/A | 144 |
| Common Stock Issued | 0 | 4,121 | 4,880 | N/A | 675 |
| Other Financing Activity | 723 | 0 | 3,422 | 3,327 | 0 |
| Financing Cash Flow | $723 | $4,121 | $8,127 | $3,327 | $819 |
| Exchange Rate Effect | -31 | 8 | -11 | N/A | -7 |
| Beginning Cash Position | 7,076 | 6,196 | 63 | 146 | 19 |
| End Cash Position | 3,848 | 7,076 | 6,196 | 3,406 | 63 |
| Net Cash Flow | $-3,197 | $873 | $6,144 | $3,260 | $50 |
| Free Cash Flow | |||||
| Operating Cash Flow | -3,921 | -3,248 | -2,090 | -67 | -768 |
| Free Cash Flow | -3,921 | -3,248 | -2,090 | -67 | -768 |